Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease

PLoS ONE

Volumn 5, Issue 8, 2010, Pages

  Jung, Oliver ^a,b   Jansen, Felix ^a   Mieth, Anja ^a   Barbosa Sicard, Eduardo ^b   Pliquett, Rainer U ^a,b   Babelova, Andrea ^a   Morisseau, Christophe ^c   Hwang, Sung H ^c   Tsai, Cindy ^c   Hammock, Bruce D ^c   Schaefer, Liliana ^b   Geisslinger, Gerd ^b   Amann, Kerstin ^d   Brandes, Ralf P ^a  

^a GOETHE UNIVERSITY MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYICOSATETRAENOIC ACID; 4 [4 (3 ADAMANTAN 1 YL UREIDO)CYCLOHEXYLOXY]BENZOIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; ARACHIDONIC ACID; CYTOCHROME P450; EPOXYICOSATRIENOIC ACID; FENBENDAZOLE; HYDROLASE; HYDROLASE INHIBITOR; HYDROXYICOSATETRAENOIC ACID; ICOSATETRAENOIC ACID; LIPOXYGENASE; PLACEBO; RAMIPRIL; SOLUBLE EPOXIDE HYDROLASE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; EPOXIDE; EPOXIDE HYDROLASE;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; ENZYME INHIBITION; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; KIDNEY INJURY; MOUSE; NONHUMAN; PEROXIDATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RENAL PROTECTION; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; NEPHRECTOMY; PATHOLOGY; PROTEINURIA; SOLUBILITY;

ANIMALIA; MUS;

ALBUMINURIA; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE PROGRESSION; ENZYME INHIBITORS; EPOXIDE HYDROLASES; EPOXY COMPOUNDS; KIDNEY FAILURE, CHRONIC; LIPOXYGENASE; MICE; NEPHRECTOMY; PROTEINURIA; SOLUBILITY;

EID: 77957821760     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011979     Document Type: Article

References (40)

1. Fleming I (2008) Vascular cytochrome p450 enzymes: physiology and pathophysiology. Trends Cardiovasc Med 18: 20-25.
2. Imig JD, Navar LG, Roman RJ, Reddy KK, Falck JR (1996) Actions of epoxygenase metabolites on the preglomerular vasculature. J Am Soc Nephrol 7: 2364-2370.
3. Arand M, Cronin A, Adamska M, Oesch F (2005) Epoxide hydrolases: structure, function, mechanism, and assay. Methods Enzymol 400: 569-588.
4. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, et al. (2000) Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87: 992-998.
5. Chiamvimonvat N, Ho CM, Tsai HJ, Hammock BD (2007) The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 50: 225-237.
6. Revermann M (2010) Pharmacological inhibition of the soluble epoxide hydrolase-from mouse to man. Curr Opin Pharmacol 10: 173-178.
7. Jung O, Brandes RP, Kim IH, Schweda F, Schmidt R, et al. (2005) Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension. Hypertension 45: 759-765.
8. Revermann M, Schloss M, Barbosa-Sicard E, Mieth A, Liebner S, et al. (2010) Soluble Epoxide Hydrolase Deficiency Attenuates Neointima Formation in the Femoral Cuff Model of Hyperlipidemic Mice. Arterioscler Thromb Vasc Biol 30: 909-914.
9. Revermann M, Barbosa-Sicard E, Dony E, Schermuly RT, Morisseau C, et al. (2009) Inhibition of the soluble epoxide hydrolase attenuates monocrotalineinduced pulmonary hypertension in rats. J Hypertens 27: 322-331.
10. Zhao X, Yamamoto T, Newman JW, Kim IH, Watanabe T, et al. (2004) Soluble epoxide hydrolase inhibition protects the kidney from hypertensioninduced damage. J Am Soc Nephrol 15: 1244-1253.
11. Imig JD, Zhao X, Zaharis CZ, Olearczyk JJ, Pollock DM, et al. (2005) An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46: 975-981.
12. Manhiani M, Quigley JE, Knight SF, Tasoobshirazi S, Moore T, et al. (2009) Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. Am J Physiol Renal Physiol 297: F740-F748.
13. Klahr S, Morrissey J (2003) Progression of chronic renal disease. Am J Kidney Dis 41: S3-S7.
14. Yu HT (2003) Progression of chronic renal failure. Arch Intern Med 163: 1417-1429.
15. Shimamura T, Morrison AB (1975) A progressive glomerulosclerosis occurring in partial five-sixths nephrectomized rats. Am J Pathol 79: 95-106.
16. Anderson S, Meyer TW, Rennke HG, Brenner BM (1985) Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. J Clin Invest 76: 612-619.
17. Griffin KA, Picken M, Bidani AK (1994) Method of renal mass reduction is a critical modulator of subsequent hypertension and glomerular injury. J Am Soc Nephrol 4: 2023-2031.
18. Ibrahim HN, Hostetter TH (1998) The renin-aldosterone axis in two models of reduced renal mass in the rat. J Am Soc Nephrol 9: 72-76.
19. Ma LJ, Fogo AB (2003) Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int 64: 350-355.
20. Hwang SH, Tsai HJ, Liu JY, Morisseau C, Hammock BD (2007) Orally bioavailable potent soluble epoxide hydrolase inhibitors. J Med Chem 50: 3825-3840.
21. Haas CS, Amann K, Schittny J, Blaser B, Muller U, et al. (2003) Glomerular and renal vascular structural changes in alpha8 integrin-deficient mice. J Am Soc Nephrol 14: 2288-2296.
22. Dimmler A, Haas CS, Cho S, Hattler M, Forster C, et al. (2003) Laser capture microdissection and real-time PCR for analysis of glomerular endothelin-1 gene expression in mesangiolysis of rat anti-Thy 1.1 and murine Habu Snake Venom glomerulonephritis. Diagn Mol Pathol 12: 108-117.
23. Veniant M, Heudes D, Clozel JP, Bruneval P, Menard J (1994) Calcium blockade versus ACE inhibition in clipped and unclipped kidneys of 2K-1C rats. Kidney Int 46: 421-429.
24. Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck JR, Fleming I, et al. (2005) Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxiainduced endothelial cell migration and angiogenesis. J Cell Sci 118: 5489-5498.
25. Imig JD (2005) Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol Renal Physiol 289: F496-F503.
26. Loch D, Hoey A, Morisseau C, Hammock BO, Brown L (2007) Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys 47: 87-98.
27. Capdevila JH, Falck JR (2001) The CYP P450 arachidonic acid monooxygenases: from cell signaling to blood pressure regulation. Biochem Biophys Res Commun 285: 571-576.
28. Moreno C, Maier KG, Hoagland KM, Yu M, Roman RJ (2001) Abnormal pressure-natriuresis in hypertension: role of cytochrome P450 metabolites of arachidonic acid. Am J Hypertens 14: 90S-97S.
29. Chamberlain RM, Shirley DG (2007) Time course of the renal functional response to partial nephrectomy: measurements in conscious rats. Exp Physiol 92: 251-262.
30. Chiurchiu C, Remuzzi G, Ruggenenti P (2005) Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the metaanalyses. J Am Soc Nephrol 16 Suppl 1: S58-S63.
31. Dorrance AM, Rupp N, Pollock DM, Newman JW, Hammock BD, et al. (2005) An epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid (AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 46: 842-848.
32. Olearczyk JJ, Quigley JE, Mitchell BC, Yamamoto T, Kim IH, et al. (2009) Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Goto-Kakizaki rats. Clin Sci (Lond) 116: 61-70.
33. Fornage M, Hinojos CA, Nurowska BW, Boerwinkle E, Hammock BD, et al. (2002) Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats. Hypertension 40: 485-490.
34. Simpkins AN, Rudic RD, Schreihofer DA, Roy S, Manhiani M, et al. (2009) Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection. Am J Pathol 174: 2086-2095.
35. Sinal CJ, Miyata M, Tohkin M, Nagata K, Bend JR, et al. (2000) Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation. J Biol Chem 275: 40504-40510.
36. Parrish AR, Chen G, Burghardt RC, Watanabe T, Morisseau C, et al. (2009) Attenuation of cisplatin nephrotoxicity by inhibition of soluble epoxide hydrolase. Cell Biol Toxicol 25: 217-225.
37. Hao CM, Breyer MD (2007) Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int 71: 1105-1115.
38. Guasch A, Zayas CF, Badr KF (1999) MK-591 acutely restores glomerular size selectivity and reduces proteinuria in human glomerulonephritis. Kidney Int 56: 261-267.
39. Ryan A, Godson C (2010) Lipoxins: regulators of resolution. Curr Opin Pharmacol 10: 166-172.
40. Ma J, Natarajan R, LaPage J, Lanting L, Kim N, et al. (2005) 12/15-lipoxygenase inhibitors in diabetic nephropathy in the rat. Prostaglandins Leukot Essent Fatty Acids 72: 13-20.